NUREXONE BIOLOGIC INC. Cash Flow-to-Debt Ratio
NUREXONE BIOLOGIC INC. cash flow-to-debt ratio. NUREXONE BIOLOGIC INC. (J90) has a Cash Flow-to-Debt Ratio of -0.89x as of December 2025, meaning its operating cash flow of €-1.17 Million could theoretically repay -1% of its total liabilities (€1.32 Million) in one year. See J90 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of NUREXONE BIOLOGIC INC. (2021–2025)
Cash flow-to-debt ratio of NUREXONE BIOLOGIC INC. from 2021 to 2025. Historical debt coverage capacity for NUREXONE BIOLOGIC INC. across 5 annual periods. Also explore J90 shareholders equity momentum to track the company's year-over-year net asset growth rate.
NUREXONE BIOLOGIC INC. Cash Flow-to-Debt Ratio by Year (2021–2025)
NUREXONE BIOLOGIC INC. cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for NUREXONE BIOLOGIC INC.. For the full cash flow conversion analysis, see J90 operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.40x | €-4.51 Million | €1.32 Million | ▲ +52.6% |
| 2024 | -7.19x | €-4.89 Million | €680.00K | ▼ -384.2% |
| 2023 | -1.48x | €-2.94 Million | €1.98 Million | ▲ +73.1% |
| 2022 | -5.51x | €-3.85 Million | €698.00K | ▼ -642.4% |
| 2021 | -0.74x | €-1.23 Million | €1.66 Million | — |